Premium
Early experience of implantation of the new CoreValve ® Evolut ™ in degenerated bioprosthetic aortic valves
Author(s) -
Fairley Sarah L.,
Jeganathan Reuben,
Manoharan Ganesh,
Spence Mark S.
Publication year - 2013
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.25125
Subject(s) - medicine , stenosis , cardiology , stroke (engine) , regurgitation (circulation) , aortic valve stenosis , mortality rate , aortic valve replacement , aortic valve , surgery , mechanical engineering , engineering
Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis in high‐risk patients. The PARTNER trial demonstrated equivalent 1‐year survival rates between patients randomized to TAVI versus conventional surgery (Leon et al., N Engl J Med 2010;363:1597–1607), with sustained benefit up to 2 years (Makkar et al., NEJM 2012;366:1696–1704). Recently, the ADVANCE registry cited all‐cause mortality rates of 4.5%, 12.8%, and 17.9% at 30‐days, 6 months, and 1‐year following TAVI in 1,015 high‐risk patients (Linke, TCT 2012, 2012). In addition, TAVI was demonstrated to be a feasible treatment for severe native valve regurgitation in a series of 31 high‐risk patients. The all‐cause 30‐day mortality rate was 6.4%, with a 30‐day major stroke rate of 6.4%. At 1‐year, the all‐cause mortality rate was 12.5% (Roy et al., J Am Coll Cardiol 2012;60(17S):B264). We report the successful transcatheter implantation of the new CoreValve ® Evolut ™ in two patients with regurgitant aortic bioprostheses. © 2013 Wiley Periodicals, Inc.